RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that Geert Cauwenbergh, Dr. Med. Sc. has been appointed as the Company’s President and Chief Executive Officer. Dr. Cauwenbergh brings more than 30 years of experience in the pharmaceutical industry, including a successful track record developing and commercializing dermatological drugs. Dr. Cauwenbergh will also serve as a director on the Company’s board.
“RXi’s next generation RNAi platform shows great promise, and I am excited to be joining this science-driven company,” stated Dr. Cauwenbergh. “I look forward to working closely with the RXi team as we progress the Company’s lead product candidate for dermal scarring, RXI-109, into human clinical trials in 2012, while also working to create long-term shareholder value through the advancement of RXi’s robust platform.”
Prior to joining RXi, Dr. Cauwenbergh served as Chairman and Chief Executive Officer of Barrier Therapeutics, Inc., a publicly-traded biopharmaceutical company he founded in 2001 that focused on dermatology drug development. Barrier was acquired by Stiefel Laboratories, Inc. in 2008. Prior to founding Barrier, Dr. Cauwenbergh held a number of ascending senior management positions at Johnson & Johnson, where he was employed for 23 years. As Vice President, Research and Development for Johnson & Johnson’s Skin Research Center, he was responsible for the worldwide research and development of all skin care products for the Johnson & Johnson consumer companies. He is a member of the board of directors of Ablynx NV and Euroscreen S.A., both European biotechnology companies. In 2005, Dr. Cauwenbergh was inducted into the New Jersey High-Tech Hall of Fame, and, from 2009 to 2010, he served as Chairman of the Board of Trustees of BioNJ. He has authored more than 100 publications and has been a guest editor for a number of books in mycology and infectious diseases. Dr. Cauwenbergh received his Doctorate in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine (Belgium), where he also completed his masters and undergraduate work.